FMP
Longeveron Inc.
LGVN
NASDAQ
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
1.65 USD
0.05 (3.03%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.longeveron.comexchange
NASDAQ
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
CIK
0001721484
ISIN
US54303L1044
CUSIP
54303L104
Address
1951 NW 7th Avenue
Phone
305 909 0840
Country
US
Employee
23
IPO Date
Feb 12, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
LGVN Financial Summary
CIK
0001721484
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
54303L104
ISIN
US54303L1044
Country
US
Price
1.65
Beta
0.35
Volume Avg.
482.19k
Market Cap
24.48M
Shares
-
52-Week
0.771-14.8
DCF
-0.87
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.29
P/B
-
Website
https://www.longeveron.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LGVN News
It looks like there's no news available.
